| 2026-07-03 | Contractile effects of albiglutide in the human and mouse atrium Neumann J, Jarikova M, Kirchhefer U, Hofmann B, Gergs U. | Front Endocrinol (Lausanne) |
| 2026-01-01 | Albiglutide and atrial fibrillation in patients with Type 2 diabetes and established cardiovascular disease: insights from the Harmony Outcomes trial Krychtiuk KA, Marquis-Gravel G, Murphy S, Chiswell K, Green JB, Leiter LA, Lopes RD, Del Prato S, McMurray JJV, Hernandez AF, Granger CB. | Eur J Prev Cardiol |
| 2024-07-01 | Effects of albiglutide on myocardial infarction and ischaemic heart disease outcomes in patients with type 2 diabetes and cardiovascular disease in the Harmony Outcomes trial Krychtiuk KA, Marquis-Gravel G, Murphy S, Alexander KP, Chiswell K, Green JB, Leiter LA, Lopes RD, Del Prato S, Jones WS, McMurray JJV, Hernandez AF, Granger CB. | Eur Heart J Cardiovasc Pharmacother |
| 2024-06-01 | Efficacy and safety of albiglutide, a once-weekly glucagon-like peptide-1 receptor agonist, in patients with type 2 diabetes: A systematic review and meta-analysis Kamrul-Hasan ABM, Dutta D, Nagendra L, Bhattacharya S, Singla R, Kalra S. | Medicine (Baltimore) |
| 2024-02-06 | Effect of albiglutide on cardiovascular outcomes in older adults: A post hoc analysis of a randomized controlled trial Gilbert MP, Skelly J, Hernandez AF, Green JB, Krychtiuk KA, Granger CB, Leiter LA, McMurray JJV, Del Prato S, Pratley RE. | Diabetes Obes Metab |
| 2023-12-14 | Brain uptake pharmacokinetics of albiglutide, dulaglutide, tirzepatide, and DA5-CH in the search for new treatments of Alzheimer's and Parkinson's diseases Rhea EM, Babin A, Thomas P, Omer M, Weaver R, Hansen K, Banks WA, Talbot K. | Tissue Barriers |
| 2022-09-09 | Albiglutide in patients with type 2 diabetes and heart failure: a post-hoc analysis from Harmony Outcomes Ferreira JP, Sharma A, Vasques-Nóvoa F, Angélico-Gonçalves A, Leite AR, Borges-Canha M, Carvalho D, Packer M, Zannad F, Leite-Moreira A, Neves JS. | Eur J Heart Fail |
| 2021-11-01 | Response to Comment on Rosenstock et al. Impact of a Weekly Glucagon-Like Peptide 1 Receptor Agonist, Albiglutide, on Glycemic Control and on Reducing Prandial Insulin Use in Type 2 Diabetes Inadequately Controlled on Multiple Insulin Therapy: A Randomized Trial. Diabetes Care 2020;43:2509-2518 Rosenstock J. | Diabetes Care |
| 2021-11-01 | Comment on Rosenstock et al. Impact of a Weekly Glucagon-Like Peptide 1 Receptor Agonist, Albiglutide, on Glycemic Control and on Reducing Prandial Insulin Use in Type 2 Diabetes Inadequately Controlled on Multiple Insulin Therapy: A Randomized Trial. Diabetes Care 2020;43:2509-2518 Marathe CS, Jones KL, Rayner CK, Wu T, Horowitz M. | Diabetes Care |
| 2020-07-21 | Impact of a Weekly Glucagon-Like Peptide 1 Receptor Agonist, Albiglutide, on Glycemic Control and on Reducing Prandial Insulin Use in Type 2 Diabetes Inadequately Controlled on Multiple Insulin Therapy: A Randomized Trial Rosenstock J, Nino A, Soffer J, Erskine L, Acusta A, Dole J, Carr MC, Mallory J, Home P. | Diabetes Care |
| 2020-06-01 | Randomized 52-week Phase 2 Trial of Albiglutide Versus Placebo in Adult Patients With Newly Diagnosed Type 1 Diabetes Pozzilli P, Bosi E, Cirkel D, Harris J, Leech N, Tinahones FJ, Vantyghem MC, Vlasakakis G, Ziegler AG, Janmohamed S. | J Clin Endocrinol Metab |
| 2019-04-18 | Efficacy and safety of an albiglutide liquid formulation compared with the lyophilized formulation: A 26-week randomized, double-blind, repeat-dose study in patients with type 2 diabetes mellitus Shaddinger BC, Soffer J, Vlasakakis G, Shabbout M, Weston C, Nino A. | Diabetes Res Clin Pract |
| 2019-03-13 | PANCREATIC SAFETY IN STUDIES OF THE GLUCAGON-LIKE PEPTIDE-1 RECEPTOR AGONIST ALBIGLUTIDE Al-Kawas F, Anderson MA, Enns R, Wilson TH, Johnson S, Mallory JM. | Endocr Pract |
| 2018-12-01 | Cardiovascular benefit of albiglutide Lim GB. | Nat Rev Cardiol |
| 2018-10-02 | Albiglutide and cardiovascular outcomes in patients with type 2 diabetes and cardiovascular disease (Harmony Outcomes): a double-blind, randomised placebo-controlled trial Hernandez AF, Green JB, Janmohamed S, D'Agostino RB, Granger CB, Jones NP, Leiter LA, Rosenberg AE, Sigmon KN, Somerville MC, Thorpe KM, McMurray JJV, Del Prato S, Harmony Outcomes committees and investigators. | Lancet |